New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 5, 2014
08:25 EDTMDCOThe Medicines Co. subsidiary awarded contract worth up to $90M
The Medicines Company announced that Rempex Pharmaceuticals, a wholly owned subsidiary, has been awarded a contract by the Biomedical Advanced Research and Development Authority, or BARDA, worth up to $90M to support the development of Carbavance. Carbavance is a combination of a carbapenem antibiotic with a novel beta-lactamase inhibitor for treatment of multi-drug resistant gram-negative infections. The BARDA contract is a cost-sharing arrangement that includes non-clinical development activities, clinical studies, manufacturing, and associated regulatory activities designed to gain U.S. approval of Carbavance for treatment of serious gram-negative infections. Studies are also planned to assess the potential usefulness of Carbavance for treatment of certain gram-negative bioterrorism agents. The contract includes an initial commitment of $19.8M and subsequent option periods over 5 years that, if completed, would bring the total value of the award to approximately $90M.
News For MDCO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2015
07:10 EDTMDCOThe Medicines Co. says exploring range of strategic-partnering options
07:10 EDTMDCOThe Medicines Co. reports Q2 adjusted EPS (65c), consensus (48c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use